Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 1 FA rating(s) are green whileLNTH’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 6 TA indicator(s) are bullish while LNTH’s TA Score has 4 bullish TA indicator(s).
EBS (@Pharmaceuticals: Other) experienced а +27.59% price change this week, while LNTH (@Pharmaceuticals: Other) price change was +4.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.80%. For the same industry, the average monthly price growth was +5.61%, and the average quarterly price growth was +19185.52%.
EBS is expected to report earnings on Jul 25, 2024.
LNTH is expected to report earnings on Aug 01, 2024.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
EBS | LNTH | EBS / LNTH | |
Capitalization | 120M | 4.27B | 3% |
EBITDA | -518.2M | 491M | -106% |
Gain YTD | 131.250 | 28.500 | 461% |
P/E Ratio | 17.73 | 12.93 | 137% |
Revenue | 1.02B | 1.3B | 79% |
Total Cash | 112M | 714M | 16% |
Total Debt | 860M | 617M | 139% |
EBS | LNTH | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 27 | |
SMR RATING 1..100 | 98 | 18 | |
PRICE GROWTH RATING 1..100 | 34 | 40 | |
P/E GROWTH RATING 1..100 | 16 | 99 | |
SEASONALITY SCORE 1..100 | 9 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (63) in the Biotechnology industry is in the same range as LNTH (69) in the Medical Specialties industry. This means that EBS’s stock grew similarly to LNTH’s over the last 12 months.
LNTH's Profit vs Risk Rating (27) in the Medical Specialties industry is significantly better than the same rating for EBS (100) in the Biotechnology industry. This means that LNTH’s stock grew significantly faster than EBS’s over the last 12 months.
LNTH's SMR Rating (18) in the Medical Specialties industry is significantly better than the same rating for EBS (98) in the Biotechnology industry. This means that LNTH’s stock grew significantly faster than EBS’s over the last 12 months.
EBS's Price Growth Rating (34) in the Biotechnology industry is in the same range as LNTH (40) in the Medical Specialties industry. This means that EBS’s stock grew similarly to LNTH’s over the last 12 months.
EBS's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for LNTH (99) in the Medical Specialties industry. This means that EBS’s stock grew significantly faster than LNTH’s over the last 12 months.
EBS | LNTH | |
---|---|---|
RSI ODDS (%) | 2 days ago85% | 2 days ago75% |
Stochastic ODDS (%) | 2 days ago87% | 2 days ago81% |
Momentum ODDS (%) | 2 days ago76% | 4 days ago77% |
MACD ODDS (%) | 2 days ago60% | N/A |
TrendWeek ODDS (%) | 2 days ago76% | 2 days ago78% |
TrendMonth ODDS (%) | 2 days ago73% | 2 days ago77% |
Advances ODDS (%) | 11 days ago77% | 3 days ago79% |
Declines ODDS (%) | 9 days ago87% | 13 days ago74% |
BollingerBands ODDS (%) | 2 days ago85% | 2 days ago74% |
Aroon ODDS (%) | 2 days ago83% | 2 days ago79% |
A.I.dvisor tells us that EBS and INDV have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EBS and INDV's prices will move in lockstep.
Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
---|---|---|---|---|
EBS | 100% | +5.31% | ||
INDV - EBS | 30% Poorly correlated | -2.13% | ||
ZOM - EBS | 29% Poorly correlated | -5.75% | ||
SNDL - EBS | 27% Poorly correlated | -7.17% | ||
ACET - EBS | 27% Poorly correlated | +1.91% | ||
LNTH - EBS | 26% Poorly correlated | -1.76% | ||
More |
A.I.dvisor tells us that LNTH and ACET have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LNTH and ACET's prices will move in lockstep.
Ticker / NAME | Correlation To LNTH | 1D Price Change % | ||
---|---|---|---|---|
LNTH | 100% | -1.76% | ||
ACET - LNTH | 32% Poorly correlated | +1.91% | ||
EBS - LNTH | 26% Poorly correlated | +5.31% | ||
SNDL - LNTH | 26% Poorly correlated | -7.17% | ||
LFCR - LNTH | 24% Poorly correlated | +1.73% | ||
ZTS - LNTH | 23% Poorly correlated | +0.20% | ||
More |